by Oscar Jofre | Jul 1, 2022 | Capital Markets, Capital Raising, Compliance
Each year, an estimated $2 trillion from illicit activities is laundered. This poses a significant challenge to financial institutions, requiring onerous efforts to verify that individuals involved in financial transactions are who they claim to be. This is where KYC,...
by Oscar Jofre | Jun 29, 2022 | Capital Markets, Capital Raising
The world of private equity is shrouded in a certain amount of mystery. What data do private equity firms use when making their investment decisions? What kind of research is needed to identify opportunities in this market? With the private equity markets raising over...
by Oscar Jofre | Jun 27, 2022 | Capital Markets, Capital Raising, KoreConX, KorePartner
Throughout June, we were happy to host another set of excellent speakers to add to our KoreTalkX series, covering timely topics like digital securities, RegA+ for cannabis, and the potential RegA+ unlocks for companies in the Medtech space. Keep reading to explore...
by Oscar Jofre | Jun 22, 2022 | Capital Raising, KoreConX, SEC
With our KoreSummit on RegA + for Medtech companies quickly approaching, we’d like to introduce the speakers we are thrilled to have for this informative event an exciting and life-changing industry. It is time to meet your MedTech A+ Team. Dawson Russel A...
by Oscar Jofre | Jun 15, 2022 | Capital Markets, Capital Raising, Regulation
With all the turbulence in the public markets, private markets look even more attractive to investors. The private markets are 4x the size of public markets. Investors are and will continue to look for investment opportunities and right now, there is a lot of private...
by Oscar Jofre | Jun 13, 2022 | Capital Markets, Capital Raising, Regulation
Private equity’s primetime has arrived! This stems from a number of reasons, including favorable economic conditions for the private capital market. In fact, 42% of private equity limited partners report a 16% net return in this space. Here are three factors in...
